来源:药渡撰文:幻目 编辑:维他命2025年已过大半,各大药企陆续交出上半年“成绩单”。在医药行业政策调整、市场竞争加剧的背景下,有的企业凭借核心产品放量实现高速增长,有的则因行业周期或战略调整短期承压。今天,我们就来盘点一下2025年上半年药企的业绩表现,看看哪些企业成为“黑马”,哪些仍在转型路上蓄力。PART.01业绩亮眼:创新药、国际化布局成增长引擎NO.1 通化东宝胰岛素龙头“王者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.